BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...

Operator Welcome to BioNTech's fourth quarter and full year 2024 earnings call. I would like to hand the call over to Michael ...

周一，Jefferies重申了对BioNTech SE（NASDAQ:BNTX）的股票评级和目标价，维持买入评级，目标价为149.00美元。此次重申是在该公司最新季度财报发布后做出的。财报显示，公司收入约为11.9亿欧元，略高于市场预期的11.8亿欧元。得益于运营支出的降低，每股收益（EPS）达到1.08欧元，同样超过了市场预期的0.77欧元。根据 InvestingPro ...

BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key ...

这家德国生物科技公司第四季度每股收益达到€1.08，超过分析师预期。营收为€11.9亿，高于€11.2亿的市场预期。 然而，BioNTech预计2025年营收为€17亿至€22亿，低于市场预期，反映出其新冠疫苗需求持续下降。

Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seventeen analysts that are covering the firm, Marketbeat Ratings reports. Three ...

Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan- ...

Wall Street expects BioNTech SE BNTX to report quarterly earnings at 58 cents per share on revenue of $1.15 billion before ...